Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial

Not Recruiting

Trial ID: NCT01756833


The primary aim of this study is to determine if doxycycline (100 mg bid) will inhibit (by at least 40%) the increase in greatest transverse diameter of small abdominal aortic aneurysms (3.5-5.0 cm in men, 3.5-4.5 cm in women) over a 24-month period of observation in comparison to a placebo-treated control group.

Official Title

Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT)

Stanford Investigator(s)

Ronald L. Dalman MD
Ronald L. Dalman MD

Dr. Walter C. Chidester Professor


Inclusion Criteria:

   - Patients 55 years of age or older, women post-surgical menopause or at least two years
   since last menses if natural menopause.

   - CT scan documented infrarenal abdominal aortic aneurysm with maximum transverse
   diameter larger than 35 mm and no greater than 50 mm, in men, and larger than 35 mm
   and no greater than 45 mm in women.

Exclusion Criteria:

   - Patients will be excluded from the study if they are unable to give their own informed
   consent to participate.

   - have symptoms related to abdominal aortic aneurysm.

   - have other intra-abdominal vascular pathology that may require repair within 24 months
   (e.g., renal artery stenosis, large iliac artery aneurysms, iliac occlusive disease,
   aneurysmal involvement of the renal artery).

   - have had previous abdominal aortic aneurysm repair by open surgical or endovascular

   - have an active malignancy with life expectancy less than two years.

   - have an allergy to tetracycline.

   - are currently or have been recently treated (previous six months) with tetracycline

   - they are currently taking anti-seizure medicines metabolized by pathways influenced by
   doxycycline (e.g., carbamazepine, phenytoin, and barbiturates).

   - stage II hypertension (patients whose blood pressure is persistently in the range of
   systolic > 160 mm Hg or diastolic > 100 mm Hg despite primary physician's best effort
   to achieve adequate therapy.

   - have dialysis dependent renal failure or impending dialysis treatment for renal

   - have a chronic infection requiring long-term (> 2 weeks) antibiotics.

   - have known genetic syndromes responsible for the abdominal aortic aneurysm (e.g.,
   Marfan's Syndrome).

   - are under treatment with systemic immunosuppressive agents.

   - could become pregnant.

   - are not good candidates for clinical trial participation.

   - are enrolled in another clinical trial.


drug: Placebo

drug: Doxycycline

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Lori McDonnell